Â鶹ŮÓÅ

Novo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug in the coming quarters, it said on Thursday, as the company struggles to keep up with soaring U.S. demand. (Skydsgaard, 8/10)

As a new class of obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for nearly half of the patients with insurance claims for GLP-1 prescriptions in 2022. (Palmer, 8/10)

The accrediting association for psychedelic practitioners has outlined what it says are the first set of professional guidelines for psychedelic-assisted therapy. The principles outlined by the American Psychedelic Practitioners Association aim to bring structure to the field amid rapidly growing interest in incorporating psychedelics like psilocybin and MDMA into mental health treatment. (Goldman, 8/10)

Pharmacists at the James A. Haley Veterans' Hospital in Tampa have passed a vote of no confidence in leadership with the health system, citing poor working conditions and a lack of support from management. The pharmacists are members of the American Federation of Government Employees. Union representatives say pharmacists have experienced significant changes in workload in recent years as several full-time staff members have left. (Colombini, 8/9)

Your prescription from OhioHealth may arrive by drone one day. The operator of hospitals including Grant Medical Center and Riverside Methodist Hospital has struck a partnership with drone company Zipline that will allow OhioHealth to deliver prescriptions directly to patients' homes and move lab samples and supplies between OhioHealth facilities. (Williams, 8/9)

After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year. (Wosen, 8/9)

Biotech giant Regeneron agreed Wednesday to pay $109 million for Boston-based Decibel Therapeutics, the third buyout in the past year of Massachusetts companies developing treatments for hearing loss. At the start of 2020, a trio of local biotechs — Decibel, Akouos, and Frequency Therapeutics — jockeyed for position in the vanguard of hearing restoration, drawing on expertise from Harvard, MIT, and Massachusetts Eye and Ear Infirmary. With the acquisition of Decibel, which has a gene therapy in clinical trials, all three have now been acquired, though their research will continue under new owners. (Weisman, 8/9)